GlassScriptPhysician profile
David A Diamond
NPI 1528069671
$43,513.06
in general payments reported to CMS, 2019-2025
19 companies · $7,981 in 2025
The $7,981 reported for 2025 was more than what 96% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2021: $46.22 · 2022: $196 · 2023: $312 · 2024: $16K · 2025: $7,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $2,933 · Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,099.00 |
| Travel and Lodging | $2,932.87 |
| Food and Beverage | $1,360.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23,694.23 | 2019-2025 | |
| Medtronic Vascular, INC. | $18,744.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $215.97 | 2021-2025 | |
| Boston Scientific Corporation | $146.35 | 2019-2025 | Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $137.90 | 2021-2025 | Imfinzi |
| Novocure INC. | $113.79 | 2023 | Optune |
| Myriad Genetic Laboratories, INC. | $95.74 | 2024-2025 | Myrisk |
| Daiichi Sankyo INC. | $66.87 | 2022-2024 | Enhertu |
| Teleflex LLC | $57.10 | 2024 | |
| Smith+Nephew, INC. | $48.00 | 2022 | |
| Blue Earth Diagnostics | $37.09 | 2023 | |
| Bioprotect Medical, INC. | $30.39 | 2025 | Bioprotect Balloon Implant System |
| Mim Software INC. | $22.00 | 2024 | Maestro |
| Dendreon Pharmaceuticals LLC | $21.31 | 2025 | Provenge |
| Glaxosmithkline, LLC. | $21.25 | 2023 | Bexsero |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 414 LLC | $20.61 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $18.93 | 2022 | |
| Kerecis Limited | $14.92 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Elekta, INC. | $5.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.